Lung Adenocarcinoma - Pipeline Review, H2 2012 New Report
Lung Adenocarcinoma - Pipeline Review, H2 2012, provides an overview of the Lung Adenocarcinoma therapeutic pipeline. This report provides information on the therapeutic development for Lung Adenocarcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma. 'Lung Adenocarcinoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured...
View full press release